Cargando…

Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin

A 49-year-old woman with systemic lupus erythematosus, lupus nephritis and chronic congestive heart failure presenting with “bulky” cervical lymphadenopathy was diagnosed with classic Hodgkin lymphoma (HL) stage IIIB (positron emission tomography-computed tomography (PET-CT) scan and bone marrow bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yohannan, Binoy, Rios, Adan, Buja, Maximilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451546/ https://www.ncbi.nlm.nih.gov/pubmed/36118550 http://dx.doi.org/10.14740/jh1035

Ejemplares similares

Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD)
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
por: Machet, Antoine, et al.
Publicado: (2022)

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study
por: Hutchings, Martin, et al.
Publicado: (2021)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
por: Tama, Elif, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

P1064: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY
por: Yasenchak, Chris, et al.
Publicado: (2023)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
por: Harker-Murray, Paul, et al.
Publicado: (2023)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Brentuximab Vedotin
Publicado: (2012)

Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
por: Mociková, Heidi, et al.
Publicado: (2020)

Successful treatment of disseminated interdigitating dendritic cell sarcoma with adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy
por: Lee, Suk-young, et al.
Publicado: (2012)

P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B)
por: Lee, H., et al.
Publicado: (2022)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
por: Uchimura, Ayana, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
por: Lagerlöf, Ingemar, et al.
Publicado: (2022)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
por: Nagashima, Kana, et al.
Publicado: (2020)

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study
por: Durmo, Rexhep, et al.
Publicado: (2022)

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
por: Cao, Zhi-Gang, et al.
Publicado: (2013)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Brentuximab-vedotin/nivolumab: SARS-CoV-2 infection: case report
Publicado: (2020)

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
por: Greve, Patrick, et al.
Publicado: (2023)

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
por: Chen, Robert, et al.
Publicado: (2016)

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
por: Donato, Eva M, et al.
Publicado: (2018)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
por: Raymakers, A. J. N., et al.
Publicado: (2020)

Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
por: Cunha Pereira, Tatiana, et al.
Publicado: (2020)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_01t7fe85vlfp9saatbsnj6mb3s